Skip to main content
. Author manuscript; available in PMC: 2013 Oct 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2012 Apr 16;18(10):1540–1551. doi: 10.1016/j.bbmt.2012.04.004

Figure 6. MYXV effectively eliminates CD138+ cells from primary MM patient samples.

Figure 6

(A) Primary BM from three MM patients was mock-treated or incubated with vMyx-M093L-Venus at MOI=10 for one hour, stained with antibodies against either CD138 (A) or CD34 (B) and then washed extensively. Virus produced by vMYX-M093L-Venus incorporates high levels of Venus into the virion and can be used to quantify virion binding by flow cytometry. Venus florescence from mock-treated (black line) as well as vMyx-M093L-Venus treated (red line) samples was then analyzed using flow cytometry at 0 hours and 24 hours after adsorption. Data from normal bone marrow mixed with U266 cells is shown as a comparison.